Related Experiment Videos
Haematological disturbances during long-term valproate therapy
B Brichard1, C Vermylen, J M Scheiff
1Department of Paediatric Haematology, University of Louvain Medical School, Brussels, Belgium.
European Journal of Pediatrics
|May 1, 1994
Summary
Valproate therapy can cause severe immune thrombocytopenia and bone marrow depression in children, even years after starting treatment. Discontinuing valproate led to significant improvement in the patient's condition.
Area of Science:
- Pediatric Hematology
- Clinical Pharmacology
- Dermatology
Background:
- Valproate is a widely used antiepileptic drug, often prescribed for extended periods.
- Potential adverse effects of valproate include hematological abnormalities and dermatological reactions.
Observation:
- A 14-year-old boy with mental retardation, on valproate since age 2, presented with severe thrombocytopenia, macrocytic anemia, and allergic dermatitis.
- Clinical findings included purpura, mucous bleeding, and extensive dermatitis.
- Positive direct antiplatelet antibodies and myelodysplastic abnormalities were noted in bone marrow examination.
Findings:
- Discontinuation of valproate therapy resulted in marked improvement of dermatitis and the patient's general condition.
- Normalization of the complete blood count was observed after valproate withdrawal.
- The case suggests a potential link between long-term valproate use and immune-mediated thrombocytopenia and bone marrow suppression.
Implications:
- This case highlights the importance of monitoring for rare but severe hematological and dermatological side effects of valproate, even years into therapy.
- Clinicians should consider valproate-induced immune thrombocytopenia and bone marrow toxicity in patients presenting with relevant symptoms.
- Further investigation into the mechanisms of valproate-induced myelotoxicity and immune dysregulation is warranted.